DVA

$187.503.01%-5.81

시간 외 거래: 186.62-0.88 -0.47%

Davita Inc (DVA)

Date: O: H: L: C: Vol:

전일 마감가:

$193.31

열려 있는:

$175.00

하루 거래량:

1,760,623

상대 거래량:

1.68

시가총액:

$11.96B

수익:

$13.84B

순이익/손실:

$1.10B

주가수익비율:

18.00

EPS:

$10.42

순현금흐름:

$1.49B

1W 성능:

+2.10%

1M 성능:

+7.19%

6M 성능:

+20.86%

1Y 성능:

+57.89%

1일 변동 폭

$171.15$187.91

1주일 범위

$171.15$196.97

52주 변동 폭

$101.00$247.49

Davita Inc 주식 (DVA) 회사 개요

명칭

Davita Inc

부문

Healthcare

산업

Medical Care Facilities

전화

310-536-2668

주소

2000 16TH STREET, DENVER, CO, USA

직원

78,000

@DaVita

다음 수익 날짜

null

최신 SEC 제출 서류

SEC

X에서 DVA에 대한 토론

DVA vs HCA, THC, EHC, FMS 비교

주식	가격	시가총액	매출	순이익	현금흐름	주당 순 이익
DVA Davita Inc	$187.50	$11.96B	$13.84B	$1.10B	$1.49B	$10.42
HCA Hca Healthcare Inc	$473.19	$102.45B	$76.39B	$7.81B	$7.93B	$29.08
THC Tenet Healthcare Corp	$273.25	$22.00B	$21.46B	$2.65B	$3.35B	$19.23
EHC Encompass Health Corp	$135.90	$13.36B	$6.07B	$793.80M	$464.40M	$5.99
FMS Fresenius Medical Care Ag Adr	$22.47	$11.96B	$22.44B	$1.35B	$2.03B	$1.90

Davita Inc 주식(DVA) 업그레이드 및 다운그레이드

날짜	액션	분석자	등급 변경
2026-08-07	업그레이드	TD Cowen	Hold → Buy
2026-05-06	업그레이드	Deutsche Bank	Hold → Buy
2024-03-06	개시	Barclays	Equal Weight
2023-08-07	업그레이드	UBS	Neutral → Buy
2022-11-01	다운그레이드	Deutsche Bank	Buy → Hold
2022-10-31	다운그레이드	UBS	Buy → Neutral
2022-08-19	Resumed	UBS	Buy
2022-06-21	재확인	BofA Securities	Underperform
2021-09-10	개시	Cowen	Market Perform
2021-08-12	다운그레이드	Barclays	Overweight → Equal Weight
2021-03-26	다운그레이드	BofA Securities	Neutral → Underperform
2021-01-05	다운그레이드	BofA Securities	Buy → Neutral
2020-01-24	업그레이드	Goldman	Neutral → Buy
2019-11-07	다운그레이드	Raymond James	Outperform → Mkt Perform
2019-10-25	다운그레이드	Wolfe Research	Outperform → Peer Perform
2019-09-11	다운그레이드	William Blair	Outperform → Mkt Perform
2019-07-26	다운그레이드	Robert W. Baird	Outperform → Neutral
2019-01-08	업그레이드	UBS	Sell → Neutral
2019-01-03	개시	Deutsche Bank	Buy
2018-12-14	개시	Barclays	Overweight
2018-11-28	업그레이드	Raymond James	Mkt Perform → Outperform
2018-11-16	개시	UBS	Sell
2018-11-08	다운그레이드	Raymond James	Strong Buy → Mkt Perform
2018-09-13	업그레이드	JP Morgan	Underweight → Neutral
2018-01-04	업그레이드	BofA/Merrill	Neutral → Buy
2017-12-12	업그레이드	Robert W. Baird	Neutral → Outperform
2017-12-11	업그레이드	Citigroup	Neutral → Buy
2017-12-07	업그레이드	Raymond James	Outperform → Strong Buy
2017-11-08	재확인	RBC Capital Mkts	Sector Perform
2017-10-09	다운그레이드	JP Morgan	Neutral → Underweight
2017-06-26	다운그레이드	Jefferies	Buy → Hold
2016-12-13	다운그레이드	Robert W. Baird	Outperform → Neutral

Davita Inc (DVA) 재무 분석

매출

순이익

현금흐름

주당 순 이익

Davita Inc 주식 (DVA) 내부자 거래

Javier RodgriguezJun 16 '26
Officer
거래
Proposed Sale
비용
$209.28
#주식
39,407
가치 ($)
8,247,016
#주식 총계
0
Rodriguez JavierJun 16 '26
Chief Executive Officer
거래
Sale
비용
$209.28
#주식
39,407
가치 ($)
8,247,018
#주식 총계
840,408
Kathleen WatersJun 15 '26
Officer
거래
Proposed Sale
비용
$207.84
#주식
8,950
가치 ($)
1,860,202
#주식 총계
0
Javier RodriguezJun 15 '26
Officer
거래
Proposed Sale
비용
$209.50
#주식
30,000
가치 ($)
6,285,102
#주식 총계
0
Waters Kathleen AlyceJun 15 '26
Officer
거래
Proposed Sale
비용
$207.93
#주식
6,455
가치 ($)
1,342,188
#주식 총계
0
Waters Kathleen AlyceJun 15 '26
Chief Legal & Pub. Affairs Off
거래
Sale
비용
$208.40
#주식
15,405
가치 ($)
3,210,377
#주식 총계
109,194
Rodriguez JavierJun 15 '26
Chief Executive Officer
거래
Sale
비용
$209.50
#주식
30,000
가치 ($)
6,285,090
#주식 총계
879,815
HEARTY JAMES OMay 15 '26
Chief Compliance Officer
거래
Sale
비용
$193.98
#주식
15,000
가치 ($)
2,909,745
#주식 총계
22,389
James HeartyMay 15 '26
Officer
거래
Proposed Sale
비용
$193.93
#주식
15,000
가치 ($)
2,908,950
#주식 총계
0
HEARTY JAMES OMay 14 '26
Chief Compliance Officer
거래
Option Exercise
비용
$110.63
#주식
5,784
가치 ($)
639,884
#주식 총계
41,737

내부자 거래	관계	날짜	거래	비용	#주식	가치 ($)	#주식 총계
Javier Rodgriguez	Officer	Jun 16 '26	Proposed Sale	$209.28	39,407	8,247,016	0
Rodriguez Javier	Chief Executive Officer	Jun 16 '26	Sale	$209.28	39,407	8,247,018	840,408
Kathleen Waters	Officer	Jun 15 '26	Proposed Sale	$207.84	8,950	1,860,202	0
Javier Rodriguez	Officer	Jun 15 '26	Proposed Sale	$209.50	30,000	6,285,102	0
Waters Kathleen Alyce	Officer	Jun 15 '26	Proposed Sale	$207.93	6,455	1,342,188	0
Waters Kathleen Alyce	Chief Legal & Pub. Affairs Off	Jun 15 '26	Sale	$208.40	15,405	3,210,377	109,194
Rodriguez Javier	Chief Executive Officer	Jun 15 '26	Sale	$209.50	30,000	6,285,090	879,815
HEARTY JAMES O	Chief Compliance Officer	May 15 '26	Sale	$193.98	15,000	2,909,745	22,389
James Hearty	Officer	May 15 '26	Proposed Sale	$193.93	15,000	2,908,950	0
HEARTY JAMES O	Chief Compliance Officer	May 14 '26	Option Exercise	$110.63	5,784	639,884	41,737

Davita Inc 주식(DVA)의 최신 뉴스

Oct 30, 2026

DaVita Q3 Earnings Beat Estimates on IKC Strength, Revenues Rise Y/Y - Zacks Investment Research

Oct 30, 2026

Oct 28, 2026

DaVita earnings: what to look for from DVA - Yahoo Finance

Oct 28, 2026

Oct 27, 2026

DaVita settles ADA complaint with Lexington patient - WKYT

Oct 27, 2026

Will DaVita's Q3 Earnings Reflect Improving Treatment Growth Trends? - Zacks Investment Research

Oct 27, 2026

Will DaVita's Q3 Earnings Reflect Improving Treatment Growth Trends? - TradingView

Oct 27, 2026

DaVita Brings Preventive Health Screenings Into Communities to Help Identify Hidden Health Risks - PR Newswire

Oct 27, 2026

Oct 25, 2026

How Investors Are Reacting To DaVita (DVA) Kidney Week Research Push - Yahoo Finance

Oct 25, 2026

Oct 24, 2026

DaVita Inc. (DVA) Stock Forecasts - Yahoo! Finance Canada

Oct 24, 2026

Oct 23, 2026

DaVita Inc. stock outperforms competitors despite losses on the day - MarketWatch

Oct 23, 2026

DaVita HealthCare (DVA) Falls More Steeply Than Broader Market: What Investors Need to Know - Zacks Investment Research

Oct 23, 2026

DaVita Inc. Estimates – NYSE:DVA - TradingView

Oct 23, 2026

Oct 22, 2026

DaVita Inc. stock outperforms competitors on strong trading day - MarketWatch

Oct 22, 2026

DaVita Stock Gains 55.6% Year to Date: What's Behind the Rally? - Zacks Investment Research

Oct 22, 2026

HHS Kidney Care Plan Raises Concerns for DaVita (DVA) Amid Positive Analyst Outlook - GuruFocus

Oct 21, 2026

Oct 20, 2026

DaVita Responds to HHS Kidney Care National Plan, Reaffirms Commitment to Innovation, Access and Patient Choice - PR Newswire

Oct 20, 2026

DaVita Inc. (DVA) Stock Forecasts - Yahoo Finance

Oct 20, 2026

A Look at DaVita Inc (DVA) After 6.2% Decline -- GF Value $198.0 - GuruFocus

Oct 20, 2026

Why DaVita (DVA) Stock Is Nosediving - Yahoo Finance

Oct 20, 2026

Why DaVita (DVA) Stock Is Nosediving - TradingView

Oct 20, 2026

DaVita falls 6% amid proposed kidney care plan (DVA:NYSE) - Seeking Alpha

Oct 20, 2026

DaVita Inc. stock underperforms Tuesday when compared to competitors - MarketWatch

Oct 20, 2026

HHS Launches Kidney Care National Plan, Impacting DaVita Inc (DV - GuruFocus

Oct 20, 2026

DaVita (DVA) Shares Slip Amid Trump Administration Dialysis Mark - GuruFocus

Oct 20, 2026

DaVita, Fresenius drop as HHS seeks dialysis market reforms (DVA:NYSE) - Seeking Alpha

Oct 20, 2026

Oct 19, 2026

DaVita Inc. Schedules 3rd Quarter 2026 Investor Conference Call - The Napa Valley Register

Oct 19, 2026

DaVita $15 Million Data Breach Class Action Settlement - Claim Depot

Oct 19, 2026

DaVita Inc. Schedules 3rd Quarter 2026 Investor Conference Call - DaVita Newsroom

Oct 19, 2026

Oct 16, 2026

DaVita HealthCare (DVA) Stock Moves -1.01%: What You Should Know - Zacks Investment Research

Oct 16, 2026

DaVita HealthCare (DVA) Stock Moves -1.01%: What You Should Know - Yahoo Finance

Oct 16, 2026

Oct 15, 2026

A Look at DaVita Inc (DVA) After 4.7% Gain -- GF Value $197.72 v - GuruFocus

Oct 15, 2026

DaVita Inc. stock outperforms competitors on strong trading day - MarketWatch

Oct 15, 2026

Davita Brings New Clinical Research to Asn Kidney Week, Advancing Evidence for the Next Era of Kidney Care - www.marketscreener.com

Oct 15, 2026

Why patients miss dialysis is one focus of seven studies DaVita will present. - Stock Titan

Oct 15, 2026

DaVita Inc. (DVA) Stock forecasts - Yahoo Finance UK

Oct 15, 2026

Davita Inc Share Price - DVA, RNS News, Articles, Quotes, & Charts (NYSE:DVA) - Proactive financial news

Oct 15, 2026

DaVita Inc. (DVA) Stock Forecasts - Yahoo! Finance Canada

Oct 15, 2026

Oct 14, 2026

DaVita Inc. (DVA) Stock Forecasts - Yahoo Finance

Oct 14, 2026

Oct 12, 2026

DaVita Inc. stock outperforms competitors on strong trading day - MarketWatch

Oct 12, 2026

Oct 09, 2026

DaVita Inc. stock underperforms Friday when compared to competitors despite daily gains - MarketWatch

Oct 09, 2026

Why DaVita HealthCare (DVA) Outpaced the Stock Market Today - Zacks Investment Research

Oct 09, 2026

DaVita rated Buy with 22% upside, driven by agg... - Pluang

Oct 09, 2026

DaVita: After A 25% Drop, The Buyback Machine Is Cheap Again (NYSE:DVA) - Seeking Alpha

Oct 09, 2026

Here's Why You Should Retain DaVita Stock in Your Portfolio for Now - Zacks Investment Research

Oct 09, 2026

Here's Why You Should Retain DaVita Stock in Your Portfolio for Now - TradingView

Oct 09, 2026

Here's Why You Should Retain DaVita Stock in Your Portfolio for Now - Yahoo Finance

Oct 09, 2026

Here's Why You Should Retain DaVita Stock in Your Portfolio for Now - TradingView

Oct 09, 2026

DaVita Inc. stock underperforms Friday when compared to competitors despite daily gains - MarketWatch

Oct 09, 2026

DVA와(과) 유사한 종목

Davita Inc (DVA)

Davita Inc 주식 (DVA) 회사 개요

DVA vs HCA, THC, EHC, FMS 비교

Davita Inc 주식(DVA) 업그레이드 및 다운그레이드

Davita Inc (DVA) 재무 분석

매출

순이익

현금흐름

주당 순 이익

Davita Inc 주식 (DVA) 내부자 거래

Davita Inc 주식(DVA)의 최신 뉴스

DaVita Q3 Earnings Beat Estimates on IKC Strength, Revenues Rise Y/Y - Zacks Investment Research

DaVita earnings: what to look for from DVA - Yahoo Finance

DaVita settles ADA complaint with Lexington patient - WKYT

Will DaVita's Q3 Earnings Reflect Improving Treatment Growth Trends? - Zacks Investment Research

Will DaVita's Q3 Earnings Reflect Improving Treatment Growth Trends? - TradingView

DaVita Brings Preventive Health Screenings Into Communities to Help Identify Hidden Health Risks - PR Newswire

How Investors Are Reacting To DaVita (DVA) Kidney Week Research Push - Yahoo Finance

DaVita Inc. (DVA) Stock Forecasts - Yahoo! Finance Canada

DaVita Inc. stock outperforms competitors despite losses on the day - MarketWatch

DaVita HealthCare (DVA) Falls More Steeply Than Broader Market: What Investors Need to Know - Zacks Investment Research

DaVita Inc. Estimates – NYSE:DVA - TradingView

DaVita Inc. stock outperforms competitors on strong trading day - MarketWatch

DaVita Stock Gains 55.6% Year to Date: What's Behind the Rally? - Zacks Investment Research

DaVita Stock Gains 55.6% Year to Date: What's Behind the Rally? - TradingView

DaVita Earnings Preview: What to Expect - Barchart.com

DaVita Inc. (DVA) Stock Forecasts - Yahoo Finance

HHS Kidney Care Plan Raises Concerns for DaVita (DVA) Amid Positive Analyst Outlook - GuruFocus

DaVita Responds to HHS Kidney Care National Plan, Reaffirms Commitment to Innovation, Access and Patient Choice - PR Newswire

DaVita Inc. (DVA) Stock Forecasts - Yahoo Finance

A Look at DaVita Inc (DVA) After 6.2% Decline -- GF Value $198.0 - GuruFocus

Why DaVita (DVA) Stock Is Nosediving - Yahoo Finance

Why DaVita (DVA) Stock Is Nosediving - TradingView

DaVita falls 6% amid proposed kidney care plan (DVA:NYSE) - Seeking Alpha

DaVita Inc. stock underperforms Tuesday when compared to competitors - MarketWatch

HHS Launches Kidney Care National Plan, Impacting DaVita Inc (DV - GuruFocus

DaVita (DVA) Shares Slip Amid Trump Administration Dialysis Mark - GuruFocus

DaVita, Fresenius drop as HHS seeks dialysis market reforms (DVA:NYSE) - Seeking Alpha

DaVita Inc. Schedules 3rd Quarter 2026 Investor Conference Call - The Napa Valley Register

DaVita $15 Million Data Breach Class Action Settlement - Claim Depot

DaVita Inc. Schedules 3rd Quarter 2026 Investor Conference Call - DaVita Newsroom

DaVita HealthCare (DVA) Stock Moves -1.01%: What You Should Know - Zacks Investment Research

DaVita HealthCare (DVA) Stock Moves -1.01%: What You Should Know - Yahoo Finance

A Look at DaVita Inc (DVA) After 4.7% Gain -- GF Value $197.72 v - GuruFocus

DaVita Inc. stock outperforms competitors on strong trading day - MarketWatch

Davita Brings New Clinical Research to Asn Kidney Week, Advancing Evidence for the Next Era of Kidney Care - www.marketscreener.com

Why patients miss dialysis is one focus of seven studies DaVita will present. - Stock Titan

DaVita Inc. (DVA) Stock forecasts - Yahoo Finance UK

Davita Inc Share Price - DVA, RNS News, Articles, Quotes, & Charts (NYSE:DVA) - Proactive financial news

DaVita Inc. (DVA) Stock Forecasts - Yahoo! Finance Canada

DaVita Inc. (DVA) Stock Forecasts - Yahoo Finance

DaVita Inc. stock outperforms competitors on strong trading day - MarketWatch

DaVita Inc. stock underperforms Friday when compared to competitors despite daily gains - MarketWatch

Why DaVita HealthCare (DVA) Outpaced the Stock Market Today - Zacks Investment Research

DaVita rated Buy with 22% upside, driven by agg... - Pluang

DaVita: After A 25% Drop, The Buyback Machine Is Cheap Again (NYSE:DVA) - Seeking Alpha

Here's Why You Should Retain DaVita Stock in Your Portfolio for Now - Zacks Investment Research

Here's Why You Should Retain DaVita Stock in Your Portfolio for Now - TradingView

Here's Why You Should Retain DaVita Stock in Your Portfolio for Now - Yahoo Finance

Here's Why You Should Retain DaVita Stock in Your Portfolio for Now - TradingView

DaVita Inc. stock underperforms Friday when compared to competitors despite daily gains - MarketWatch

DVA와(과) 유사한 종목